Laprysta (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilizes neuronal membranes and limits repetitive firing. Additionally, it binds to the protein CRMP2, influencing neuronal excitability and further contributing to seizure suppression.

The specific dose of Laprysta is individualized by the treating physician based on the patient’s clinical condition, prior therapy, and response. The prescriber determines the starting dose, titration schedule, and maintenance dose to achieve optimal seizure control while minimizing side effects.

The safety of lacosamide in pregnancy and lactation has not been definitively established. It is classified as having an unknown pregnancy category, so it should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Breastfeeding decisions should be made in consultation with a healthcare professional.

To request Laprysta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details, and any required import documentation.

Lacosamide offers a unique mechanism by enhancing slow sodium‑channel inactivation, which differs from agents like carbamazepine that target fast inactivation. Compared with levetiracetam, lacosamide may have a lower incidence of behavioral side effects but can affect cardiac conduction, requiring ECG monitoring in certain patients.

Laprysta tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack to protect from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Laprysta is taken orally as a tablet, usually with a glass of water. It can be taken with or without food, but consistency with meals may help reduce gastrointestinal discomfort. Swallow the tablet whole; do not crush or chew unless specifically instructed by a healthcare provider.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, which may lead to arrhythmias, and rare but severe skin reactions like Stevens‑Johnson syndrome. Additionally, patients may experience suicidal thoughts or behavior, so monitoring for mood changes is essential.

Laprysta should be avoided in individuals with known hypersensitivity to lacosamide or any tablet excipients. Patients with significant cardiac conduction disorders (e.g., second‑degree AV block) should not use it without specialist supervision. Caution is also advised for those with severe renal or hepatic impairment.